Arcturus Therapeutics announced positive Phase III trial results for the company’s mRNA vaccine candidate ARCT-154, which is intended to prevent COVID-19 caused by the SARS-CoV-2 virus.
The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans, with hundreds of presentations on cutting-edge cancer research. The presentations run the gamut from preclinical studies to late-stage clinical trials. BioSpace looks at some of the preclinical and early-stage studies presented.
Shares of Veru Inc. soared nearly 200 percent after the Florida-based company announced its Phase III COVID-19 antiviral treatment was halted early based on positive efficacy following an Independent Data Monitoring Committee’s recommendation.
AstraZeneca will showcase the company’s early oncology portfolio that it believes has the potential to transform the oncology treatment landscape at the upcoming American Association for Cancer Research (AACR) conference.
Two doses of the Pfizer Inc. and BioNTech SE COVID-19 vaccine was protective against severe disease in children aged 5 to 11 during the recent Omicron variant surge, but quickly lost most of its ability to prevent infection in the age group, according to a study by New York State researchers.
The U.S. Food and Drug Administration held a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee on Avenue Therapeutics’ IV tramadol.
U.S. health officials on Feb. 4 said they are considering lengthening the recommended interval between the first two doses of the most widely used COVID-19 vaccines to eight weeks to lower the risk of heart inflammation and improve their effectiveness.
Biogen Inc. on Feb. 3 forecast 2022 profit well below Wall Street estimates as sales of the company’s new Alzheimer’s disease drug stall amid questions over Aduhelm’s efficacy and a looming U.S. government coverage decision that could severely limit the medicine’s future use and force further cost cutting.
Roche said ongoing trials of the company’s Alzheimer’s disease drug candidate gantenerumab are designed to provide unequivocal results on efficacy as controversy continues in the United States over the benefits of a rival’s approved drug.
Belgium’s UCB is acquiring California-based Zogenix, a company focused on rare diseases, in a deal valued up to €1.7 billion ($1.9 billion).